CN114302731A - 用于治疗疾病的外泌体 - Google Patents

用于治疗疾病的外泌体 Download PDF

Info

Publication number
CN114302731A
CN114302731A CN202080042501.XA CN202080042501A CN114302731A CN 114302731 A CN114302731 A CN 114302731A CN 202080042501 A CN202080042501 A CN 202080042501A CN 114302731 A CN114302731 A CN 114302731A
Authority
CN
China
Prior art keywords
exosomes
disease
condition
disorder
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080042501.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·J·哈里里
张晓奎
叶谦
何曙阳
H·M·哈里里
N·沙
S·索曼奇
B·斯陶特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clarity Acquisition II LLC
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of CN114302731A publication Critical patent/CN114302731A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
CN202080042501.XA 2019-06-19 2020-06-19 用于治疗疾病的外泌体 Pending CN114302731A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962863767P 2019-06-19 2019-06-19
US62/863,767 2019-06-19
US201962891700P 2019-08-26 2019-08-26
US62/891,700 2019-08-26
US201962905117P 2019-09-24 2019-09-24
US62/905,117 2019-09-24
US201962924147P 2019-10-21 2019-10-21
US62/924,147 2019-10-21
PCT/US2020/038828 WO2020257720A1 (en) 2019-06-19 2020-06-19 Exosomes for disease treatment

Publications (1)

Publication Number Publication Date
CN114302731A true CN114302731A (zh) 2022-04-08

Family

ID=71662298

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080042501.XA Pending CN114302731A (zh) 2019-06-19 2020-06-19 用于治疗疾病的外泌体

Country Status (13)

Country Link
US (1) US20230181649A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986381A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022538004A (cg-RX-API-DMAC7.html)
KR (1) KR20220024060A (cg-RX-API-DMAC7.html)
CN (1) CN114302731A (cg-RX-API-DMAC7.html)
AU (1) AU2020298316A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025512A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142020A1 (cg-RX-API-DMAC7.html)
IL (1) IL288958A (cg-RX-API-DMAC7.html)
MX (1) MX2021015528A (cg-RX-API-DMAC7.html)
PH (1) PH12021553167A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020257720A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202109828B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120437174A (zh) * 2025-02-28 2025-08-08 单核细胞治疗有限公司 脐带血外泌体在制备治疗衰老引发的眼科疾病的药物中的应用
CN120927522A (zh) * 2025-10-14 2025-11-11 亿航(苏州)生物医药有限公司 辅助诊断或鉴别血管性认知障碍的标志物、试剂盒及用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
IL320107A (en) 2019-02-07 2025-06-01 Direct Biologics Llc Method for treating osteoarthritis with a combination of mesenchymal stem cell exosomes, synovial mesencymal stem cells, and scaffolds
WO2021011935A1 (en) 2019-07-18 2021-01-21 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
US20210322483A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
US20210324339A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
MX2022013301A (es) 2020-04-22 2023-02-14 Direct Biologics Llc Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.
KR102317052B1 (ko) * 2020-05-04 2021-10-25 주식회사 티에스셀바이오 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물
WO2022154149A1 (ko) * 2021-01-14 2022-07-21 (주)엑솔런스 세포외소포체를 이용한 백신 조성물
US20240307438A1 (en) * 2021-02-26 2024-09-19 The Methodist Hospital Regulatory T Cell (Treg) Extracellular Vesicle Compositions and Methods
CN113171379A (zh) * 2021-04-28 2021-07-27 奥启(深圳)创投科技有限公司 一种间充质干细胞外泌体在制备脂肪性肝病药物中的应用
CN114085817B (zh) * 2021-11-26 2025-04-15 三代康年(上海)医疗科技有限公司 一种包载microRNA的外泌体的制备方法及其产品和应用
EP4507718A4 (en) * 2022-04-08 2026-07-29 Innovative Surgical Regeneration Holdings Llc NAMPT FOR HEALING AND STIMULATING HAIR GROWTH AND/OR REGROWTH
CN117414415B (zh) * 2023-07-10 2024-10-18 中山大学·深圳 蛋白质精氨酸甲基转移酶7在促进毛发生长中的应用
KR20250033996A (ko) * 2023-08-31 2025-03-10 의료법인 성광의료재단 인간 태반 유래 중간엽 줄기 세포에서 분리된 엑소좀을 포함하는 시신경 질환 및 미토콘드리아 기능이상 질환 예방 또는 치료용 약학적 조성물
KR20250139693A (ko) * 2024-03-15 2025-09-23 가톨릭대학교 산학협력단 Ssea3 및 cd105를 발현하는 신경능 유래 코 줄기세포 유효성분으로 포함하는 알츠하이머병 예방 또는 치료용 약학적 조성물
WO2025226276A1 (en) 2024-04-25 2025-10-30 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105861430A (zh) * 2016-04-29 2016-08-17 南京大学 一种外泌体、外泌体的制备方法及其在制备治疗脓毒症药物或者制剂中的应用
WO2018083700A1 (en) * 2016-11-03 2018-05-11 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
CN108366567A (zh) * 2015-05-26 2018-08-03 细胞结构公司 使用受刺激的胎盘干细胞的血管生成
WO2019099955A1 (en) * 2017-11-16 2019-05-23 Celularity, Inc. Cultivation of placenta to isolate exosomes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2484782B1 (en) * 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
CA2705486C (en) * 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
AR075239A1 (es) * 2009-02-04 2011-03-16 Bipar Sciences Inc Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso
AU2015330855A1 (en) * 2014-10-09 2017-04-27 Celularity Inc. Placenta-derived adherent cell exosomes and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108366567A (zh) * 2015-05-26 2018-08-03 细胞结构公司 使用受刺激的胎盘干细胞的血管生成
CN105861430A (zh) * 2016-04-29 2016-08-17 南京大学 一种外泌体、外泌体的制备方法及其在制备治疗脓毒症药物或者制剂中的应用
WO2018083700A1 (en) * 2016-11-03 2018-05-11 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
WO2019099955A1 (en) * 2017-11-16 2019-05-23 Celularity, Inc. Cultivation of placenta to isolate exosomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
赵丽华 等: "exosome 及其在免疫耐受方面的作用", 生命科学, vol. 19, no. 2, 30 April 2007 (2007-04-30), pages 174 - 178 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120437174A (zh) * 2025-02-28 2025-08-08 单核细胞治疗有限公司 脐带血外泌体在制备治疗衰老引发的眼科疾病的药物中的应用
CN120927522A (zh) * 2025-10-14 2025-11-11 亿航(苏州)生物医药有限公司 辅助诊断或鉴别血管性认知障碍的标志物、试剂盒及用途

Also Published As

Publication number Publication date
BR112021025512A2 (pt) 2022-02-01
ZA202109828B (en) 2024-04-24
MX2021015528A (es) 2022-02-03
KR20220024060A (ko) 2022-03-03
AU2020298316A1 (en) 2021-12-16
CA3142020A1 (en) 2020-12-24
PH12021553167A1 (en) 2022-08-15
WO2020257720A1 (en) 2020-12-24
EP3986381A1 (en) 2022-04-27
IL288958A (en) 2022-02-01
US20230181649A1 (en) 2023-06-15
JP2022538004A (ja) 2022-08-31

Similar Documents

Publication Publication Date Title
KR20220024060A (ko) 질환 치료용 엑소좀
JP2024023185A (ja) エキソソームを単離するための胎盤の培養
JP7417301B2 (ja) 細胞培養上清および生体液からの微小胞の単離および精製のための方法
JP6755850B2 (ja) 間葉系幹細胞の使用
US9877989B2 (en) Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
EP3029061B1 (en) Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
US20230330154A1 (en) Methods of treating systemic graft- versus-host disease with extracellular vesicles
US20190353643A1 (en) Method For Sorting Highly Effective Stem Cells For Treating Immune Disorder
US20230172990A1 (en) Extracellular vesicle compositions and the use thereof in the treatment of skin conditions and in immune modulation
US20160022739A1 (en) Closed system separation of adherent bone marrow stem cells for regenerative medicine applications
PT2626417E (pt) Métodos para expansão celular e usos de células e de meios condicionados produzidos através deles para terapia
CN107106615A (zh) 胎盘来源的贴壁细胞外泌体及其用途
JP2020534344A (ja) 表皮水疱症を処置するための方法及び組成物
JP2024161089A (ja) 間葉系間質細胞を拡大するための方法
JP2017520582A (ja) 関節リウマチ治療のための間葉系間質細胞
WO2024045404A1 (zh) 一种骨髓上清液及其在细胞培养中的应用
CN115475181A (zh) 羊膜间充质干细胞源外泌体及其用途
CN117255679A (zh) 调节性t细胞(treg)胞外囊泡组合物和方法
WO2021262610A1 (en) Peripheral blood derived small pluripotent cells
JP2024509023A (ja) 肝線維化および/または肝硬変の予防および治療における使用のための、脂肪組織由来再生細胞(ADRCs)を含む医薬組成物
HK40010197A (en) Therapeutic agent for dilated cardiomyopathy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220408